The tweet was deleted by the author.
But we saved everything 🙂.
Solid Biosciences Inc. presented its next-generation gene therapy candidate, SGT-003, for Duchenne muscular dystrophy (DMD) during a high-profile Clinical Trials session last week.
Patrick González, PhD, Vice President and Head of Clinical Science at the company, shared key insights into the therapy's potential, reinforcing Solid Biosciences Inc.'s commitment to advancing treatment options for DMD. The presentation took place at a leading clinical and scientific congress focused on muscular dystrophy, strengthening industry interest in innovative approaches to address this rare genetic disorder.
Solid Biosciences Inc. recently co-hosted a webinar with Defeat Duchenne to discuss the clinical development of SGT-003 gene therapy. The company also highlighted advances in targeted genetic therapy delivery at a Boston biotech conference earlier this year. These initiatives demonstrate Solid Biosciences’ ongoing engagement with clinical and scientific communities focused on Duchenne muscular dystrophy.